Cargando…

Tumorigenic potential of circulating prostate tumor cells

Circulating tumor cells (CTCs) have received intense scientific scrutiny because they travel in the bloodstream and are therefore well situated to mediate hematogenous metastasis. However, the potential of CTCs to actually form new tumors has not been tested. Popular methods of isolating CTCs are bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carvalho, Filipe LF., Simons, Brian W., Antonarakis, Emmanuel S., Rasheed, Zeshaan, Douglas, Nora, Villegas, Daniela, Matsui, William, Berman, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717304/ https://www.ncbi.nlm.nih.gov/pubmed/23530114

Ejemplares similares

Isolation of Stem Cells from Human Pancreatic Cancer Xenografts
por: Rasheed, Zeshaan, et al.
Publicado: (2010)

Selective inhibitors of nuclear export: potential therapeutics for AR variant-expressing prostate cancer
por: Antonarakis, Emmanuel S.
Publicado: (2018)

Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2022)

AR Signaling in Human Malignancies: Prostate Cancer and Beyond
por: Antonarakis, Emmanuel S.
Publicado: (2018)

Circulating Tumor Cells in Prostate Cancer
por: Hu, Brian, et al.
Publicado: (2013)

Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
por: Crea, Francesco, et al.
Publicado: (2011)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
por: Nizialek, Emily, et al.
Publicado: (2020)

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
por: Koch, Claudia, et al.
Publicado: (2020)

Chemotherapy and its evolving role in the management of advanced prostate cancer
por: Schweizer, Michael T, et al.
Publicado: (2014)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Immunotherapy for Prostate Cancer Enters Its Golden Age
por: Boikos, Sosipatros A., et al.
Publicado: (2012)

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer
por: Suzman, Daniel L., et al.
Publicado: (2015)

Galeterone for the treatment of advanced prostate cancer: the evidence to date
por: Bastos, Diogo A, et al.
Publicado: (2016)

Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion
por: Tran, Phuoc T., et al.
Publicado: (2017)

Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
por: Golshayan, Ali R, et al.
Publicado: (2013)

Germline genetic testing in prostate cancer – further enrichment in variant histologies?
por: Markowski, Mark C., et al.
Publicado: (2018)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Pro‐tumorigenic role of ERα in prostate cancer cells
por: Furic, Luc, et al.
Publicado: (2015)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells
por: Liu, Xin, et al.
Publicado: (2015)

Isolation and characterization of circulating tumor cells in prostate cancer
por: Diamond, Elan, et al.
Publicado: (2012)

miR-17* Suppresses Tumorigenicity of Prostate Cancer by Inhibiting Mitochondrial Antioxidant Enzymes
por: Xu, Yong, et al.
Publicado: (2010)

Tumor-associated myeloid cells promote tumorigenesis of non-tumorigenic human and murine prostatic epithelial cell lines
por: Sass, Stephanie N., et al.
Publicado: (2018)

Sox9 is required for prostate development and prostate cancer initiation
por: Huang, Zhenhua, et al.
Publicado: (2012)

Applications of circulating tumor cells for prostate cancer
por: Cheng, Shirley, et al.
Publicado: (2016)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Snail depletes the tumorigenic potential of glioblastoma
por: Savary, K, et al.
Publicado: (2013)

SULF2 overexpression positively regulates tumorigenicity of human prostate cancer cells
por: Vicente, Carolina M, et al.
Publicado: (2015)

COX-2 MEDIATES PRO-TUMORIGENIC EFFECTS OF PKCε IN PROSTATE CANCER
por: Garg, Rachana, et al.
Publicado: (2018)

PAQR3 suppresses the proliferation, migration and tumorigenicity of human prostate cancer cells
por: Huang, Wenqiang, et al.
Publicado: (2016)

Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell Lines
por: Jimenez, Rosa H., et al.
Publicado: (2009)

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2020)

Diverse animal models to examine potential role(s) and mechanism of endocrine disrupting chemicals on the tumor progression and prevention: Do they have tumorigenic or anti-tumorigenic property?
por: Park, Min-Ah, et al.
Publicado: (2011)

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: Association of Gleason score and tumor stage
por: Marshall, Catherine Handy, et al.
Publicado: (2018)

A tumorigenic culprit in ES cells
por: Wells, William A.
Publicado: (2003)

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l5pggpl6q464k8ktrpaf4tnqa1